Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073460 | 0.82 | TBXA2R (0.44) | TBXAS1SMN1; SMN2KMT2ATDP1TBXA2R | |
| SCHEMBL10072887 | 0.82 | KMT2A (0.42) | TBXAS1SMN1; SMN2KMT2ATBXA2R | |
| SCHEMBL10072890 | 0.78 | KMT2A (0.39) | SMN1; SMN2SLC40A1KMT2ATDP1MEN1 | |
| SCHEMBL10073466 | 0.77 | ALDH1A1 (0.50) | SMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL10072916 | 0.76 | — | — | |
| SCHEMBL10074043 | 0.74 | ALDH1A1 (0.48) | SGMS1 | |
| SCHEMBL10072908 | 0.74 | L3MBTL1 (0.51) | KMT2ATDP1MEN1L3MBTL1 | |
| SCHEMBL10073161 | 0.74 | LMNA (0.40) | TBXAS1SMN1; SMN2TBXA2R | |
| SCHEMBL10073655 | 0.73 | ALDH1A1 (0.50) | SMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL10047436 | 0.72 | KDM4E (0.46) | SLC40A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445681-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| US-8017781-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017781-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007059219-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | PRKDC, MAP3K20, PRKACA | TBXAS1 1216/4885SMN1; SMN2 2765/4885TAAR1 3884/4885 |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | PRKDC, MAP3K20, PRKACA | TBXAS1 1216/4885SMN1; SMN2 2765/4885TAAR1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.